Omaha, NE Streck, Inc. and Biodesix®, a molecular diagnostics company advancing the development of innovative blood-based tests in oncology, have signed an agreement to make Streck the exclusive supplier of DNA and RNA tubes for Biodesix. The partnership enables Biodesix to utilize Strecks technology, including its blood collection tubes, as part of Biodesix products and services.
Strecks blood collection tubes include Cell-Free DNA BCT®, a direct-draw tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; and Cell-Free RNA BCT®, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage.
Biodesix will include Strecks blood collection tubes with GeneStrat, a targeted liquid biopsy mutation test for patients with advanced lung cancer, run in our CLIA-certified laboratory, said Gary Pestano, Ph.D., Vice President of Product Development and Operations for Biodesix. We selected Streck tubes because they effectively stabilize the circulating DNA and RNA in patient samples, allowing for convenient sample collection and shipment without the need for immediate plasma isolation.
Biodesix is developing new blood tests for their CLIA laboratory to identify patients who may benefit from targeted and immunotherapies, said Connie Ryan, President and CEO at Streck. We are pleased to partner with a company that is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance and enhanced disease monitoring to improve patient outcomes.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including GeneStrat and VeriStrat®, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel
About Streck, Inc.
Established in 1971, Streck develops and manufactures products for clinical and research laboratories. Streck’s passion for innovation, quality and service has allowed the organization to become a world leader in the development of quality control and diagnostic products that help laboratories ensure accurate and timely results for patients. Streck offers the industry’s leading automated erythrocyte sedimentation rate instrument and is a worldwide supplier of blood collection tubes that standardize methods for sample collection, stabilization and transportation. Expanding product lines include flow cytometry, body fluids and urinalysis with emerging products being developed for the burgeoning field of molecular diagnostics. For more information, visit www.streck.com.